Leap Therapeutics, Inc.
LPTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DKN-01 | Phase 2 | Colorectal Cancer | - | - |
Paclitaxel | Phase 2 | Endometrial Cancer | - | - |
Frequently asked questions
What is in Leap Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Leap Therapeutics, Inc.'s (LPTX) pipeline across Phase 2. Its lead program is DKN-01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Leap Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Leap Therapeutics, Inc. (LPTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LPTX biotech catalysts?→
Add LPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Leap Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.